From the Journals

Low-carb, plant-rich diets tied to breast cancer survival?


 

TOPLINE:

A new analysis shows a significant association between plant-rich, low-carbohydrate diets and overall survival, but not breast cancer–specific survival, among women with stage I-III breast cancer.

METHODOLOGY:

  • The diets of 9,621 women with stage I-III breast cancer from two ongoing cohort studies – the Nurses’ Health Study and Nurses’ Health Study II – were evaluated.
  • Overall low-carb, animal-rich, and plant-rich low-carb diet scores were calculated using food frequency questionnaires after breast cancer diagnosis.
  • Cox proportional hazards regression models adjusted for multiple potential confounding factors.
  • Follow-up lasted for a median of 12.4 years after breast cancer diagnosis.

TAKEAWAY:

  • Overall, 1,269 deaths due to breast cancer and 3,850 all-cause deaths occurred during the follow-up period.
  • Researchers found that greater adherence to low-carb (hazard ratio, 0.82 for quintile 5 vs. 1) and plant-rich diet (HR, 0.73 Q5 vs. 1) was associated with a significantly lower risk for overall mortality but not breast cancer–specific mortality.
  • Overall, adhering to animal-rich, low-carb diets did not significantly influence all-cause or breast cancer–specific survival rates.
  • But replacing 3% of energy intake from available carbohydrates with fish protein was associated with 17% lower risk for breast cancer–specific mortality and 15% lower risk for all-cause mortality.

IN PRACTICE:

“The findings suggest that breast cancer survivors could benefit from limiting intake of carbohydrates, especially from fruit juice, sugar-sweetened beverages, and added sugar, and increasing the amount of protein and fat, in particular from plant sources,” the authors write.

STUDY DETAILS:

The study was led by Maryam Farvid, PhD, with the Data Statistics Group, Mission Viejo, Calif. It was published online in the journal Cancer and supported by National Institutes of Health and the University of Toronto.

LIMITATIONS:

Most women were non-Hispanic White and health professionals, so the results might not generalize to other sociodemographic groups. The authors also noted potential residual confounding, despite controlling for several breast cancer risk factors.

DISCLOSURES:

Dr. Farvid is a founder of the Institute for Cancer Prevention and Healing and the Data Statistics Group.

A version of this article first appeared on Medscape.com.

Recommended Reading

Phone support helps weight loss in patients with breast cancer
Federal Practitioner
Ribociclib forestalls recurrence also in early breast cancer
Federal Practitioner
ER+/HER2– breast cancer: Is first or second line CDK4/6 inhibitor therapy better?
Federal Practitioner
Widespread carboplatin, cisplatin shortages: NCCN survey
Federal Practitioner
Breast cancer experts and other HCPs disagree on treatment strategies for early BC
Federal Practitioner
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Federal Practitioner
New study backs up capecitabine dosing practice in metastatic BC
Federal Practitioner
Less therapy may suit older patients with breast cancer
Federal Practitioner
‘New standard of care’ for capecitabine hand-foot syndrome
Federal Practitioner
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
Federal Practitioner